Positions

Dates

Title

Institution


2013-Present
 
Executive Director of Epidemiology. Direct reports: 5-8 FTEs

 Merck Research Laboratories. Provides global Epidemiology Therapeutic Area leadership for oncology, diabetes, cardiovascular, and benefit-risk assessment franchises
 
2011-2013
 
Deputy Division Director, Division of Epidemiology-I (Medical Officer Series). Direct reports: 20 FTEs [DUTIES]
 
HHS, FDA, CDER, Office of Surveillance and Epidemiology (OSE), Office of Pharmacovigilance and Epidemiology (OPE), Division of Epidemiology-I

2009-2011

Associate Director of Epidemiology (Medical Officer Series). Team members 5 [DUTIES]

HHS, FDA, CDER, Office of Surveillance and Epidemiology (OSE), Office of Pharmacovigilance and Epidemiology (OPE), Division of Epidemiology-I

2006-2011

Team Leader, Analytic Pharmacoepidemiology/ Data Management and Analysis Team (Medical Officer Series). Team members 8 [DUTIES]

HHS, FDA, CDER, Office of Surveillance and Epidemiology (formerly known as the Office of Drug Safety), Division of Epidemiology

2004-2006

Senior Medical Pharmacoepidemiologist (Level III Reviewer, Medical Officer Series) [DUTIES]

HHS, FDA, CDER, Office of Surveillance and Epidemiology (formerly known as the Office of Drug Safety), Division of Surveillance Research and Communication Support (DSRCS)

 2002-2004


Senior Medical Reviewer (Level III Reviewer, Medical Officer Series) [1] [DUTIES]

HHS, FDA, CDER, Division of Neuropharmacological Drug Products (DNDP), now divided into Divisions of Neurological (DNP) and Psychiatric Products (DPP)

2000-2002

Medical Reviewer (Level II Reviewer, Medical Officer Series) [2] [DUTIES]

Office of Drug Evaluation I (ODE I), Division of Neuropharmacological Drug Products (DNDP), now split into Divisions of Neurological and Psychiatric Products

1996-2000

Director of Clinical Research and Medical Affairs [DUTIES]

Nutramax Laboratories, Inc., 1208 Lakeside Blvd, Edgewood, MD, 20140

 

 1988-1992

 

Primary Care Physician (General
Practitioner)


Egyptian Ministry of Health hospitals, rural health centers, Army medical centers and private practice.

 

 1986-1987

 

Medical House Officer
(internship)

 

Cairo University School of Medicine and Ministry of Health hospitals, Cairo, Egypt.

     
     


[1] Level III Senior Reviewer: “An experienced, productive, superior reviewer who makes significant contributions to applications and technical problems within his/her Division, discipline, and throughout CDER. A Senior Reviewer demonstrates a thorough command of the review process and of regulatory science. The senior reviewer adapts well to team initiatives and deadlines, requires minimal supervision, participates in CDER initiatives, and demonstrates considerable interpersonal and communication skills.” Source: CDER Reviewer Career Path Procedures for Promotion to Level III (http://cdernet/crcp/mapp3.htm).

[2] Level II Reviewer: “A reviewer who has acquired general knowledge of the review process and completed the first phase of an Individual Development Plan to meet the core competency level for his/her discipline. A reviewer understands the basic tools of regulatory drug review and is capable of producing good reviews with some supervisory guidance. He/she functions as a team player and cooperates with others involved in the drug review process.” Source: CDER Reviewer Career Path Procedures for Promotion to Level III (http://cdernet/crcp/mapp3.htm).

Comments